Articaine vs Dexmedetomidine Supplemented Articaine

Renal Failure Clinical Trial

Official title:

Articaine and Dexmedetomidine - Supplemented Articaine for Arteriovenous Fistula Creation Under Ultrasound- Guided Supraclavicular Block

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04171349
• Other study ID #: Articaine
• Status: Completed
• Phase: Early Phase 1
• Start date: June 1, 2019
• Est. completion date: November 1, 2019

Study information

• Verified date: November 2019
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study to test efficacy of adding dexmedetomidine to articaine on sensory, motor and duration of analgesia during hemodialysis fistula creation under ultrasound guided supraclavicular block

Description:

Adult fifty patient with chronic renal failure on hemodialysis, scheduled for arteriovenous fistula creation under ultrasound guided supraclavicular block. Patients were randomly allocated in two group. The articaine group (group A) received 40 ml articaine hydrochloride 2% and articaine-dexmedetomidine group (group AD) received 40 ml. Of articaine 2% mixed with dexmedetomidine (1micogram/kg)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: November 1, 2019
• Est. primary completion date: October 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 75 Years

Eligibility

Inclusion Criteria:

• adult patient with chronic renal failure on hemodialysis scheduled for radiocephalic fistula creation

Exclusion Criteria:

• Allergy to local anesthetics.

• Infection at the site of needle insertion.

• Those having international normalized ratio more than 1.5.

• Coagulopathy.

• Neuromuscular, or severe hepatic or severe pulmonary disease.

• Those having epilepsy.

• Patients who refused to participate.

Related Conditions & MeSH terms

• Renal Failure
• Renal Insufficiency

Intervention

Drug:
• Articaine
Vial
• Dexmedetomidine
Vial

Locations

Country	Name	City	State
Egypt	Ain Shams University hosptal	Cairo	Abbasya

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Sedation	Measured by Ramsay sedation scale score 3	24 hours
Primary	Duration of sensory block	Sensory block time tested by pinprick test measured in minute	24 hours
Primary	Duration of motor block	Motor block time tested by Bromage scale measured in minutes	24 hours
Secondary	Duration of analgesia	Measured by visual analog scale score 4	24 hours